Pharma & Bio
Lifestyle
G2G Bio and ImmuneOncia Rally, ABL Bio Tumbles Amid Insider Trading Probe [K-Bio Pulse]
G2G Bio and ImmuneOncia posted notable gains on Monday, while ABL Bio shares tumbled. G2G Bio rose more than 10% on expectations that competition among long-acting injectable technologies in the globa…
- 2026-09-17 07:32:02
- SONG YOUNG-DOO
Lifestyle
G2GBIO, Inc. and ImmuneOncia Therapeutics, Inc. Soar, While ABL Bio Inc. Plummets Amid ‘Insider Trading Allegations’ [Bio Market Watch]
While #G2GBIO, Inc. and #ImmuneOncia Therapeutics, Inc. posted notable gains, ABL Bio Inc.(298380)plummeted. G2GBIO, Inc. rose more than 10% on expectations that the global obesity treatment market wi…
- 2026-09-17 07:31:02
- SONG YOUNG-DOO
Technology
SK Biopharm: A Closer Look at the Opakalim Royalty Structure... Double Royalties and a Burden of Up to 28%
Attention is focusing on the dual royalty structure after #SK Biopharm—which licensed the new epilepsy drug candidate “Opacalym” (BHV-7000) from U.S. biotech firm Biohaven—agreed to pay royalties to t…
- 2026-09-16 08:41:01
- KIM SUNG-JIN
Lifestyle
INFINITT Healthcare Hits Daily Limit Up on Dividend Announcement; Samik Pharma Jumps [K-bio pulse]
South Korean healthcare stocks were mixed on Monday as investors reacted to dividend plans, patent developments, and expectations for overseas sales.INFINITT Healthcare hit its daily trading limit aft…
- 2026-09-16 08:32:02
- Kim Jinsoo
Lifestyle
INFINITT Healthcare Rises on 65.4 Billion Won Dividend… SAMIK PHARM. Co., LTD. in the Spotlight [Bio Spotlight]
On the 14th, in the pharmaceutical and biotech sector, INFINITT Healthcare(071200)shares soared to the daily price limit following news that the company would pay a cash dividend totaling 65.4 billion…
- 2026-09-16 08:31:02
- Kim Jinsoo
Technology
Humic, a Leader in Humanized Mice, Now Incorporates Toxicity… H&H Bio’s Transformation
Humic, a company specializing in efficacy evaluations using humanized mouse models, has expanded its business scope to include toxicity testing through a merger with H&H Bio, a non-clinical contract r…
- 2026-09-16 08:06:02
- NA EUN-KYUNG
Technology
Even Bill Gates Has Bet 44.6 Billion; What Lies Ahead for LGCHEM,LTD’s “Hexavalent Vaccine,” Now in Its Ninth Year of Development?
LGCHEM,LTD(051910) The research and development schedule for the “hexavalent combination vaccine” intended for supply to developing countries has been delayed yet again. Following the initial pushback…
- 2026-09-16 07:46:02
- KIM SUNG-JIN
Technology
ABL Bio Inc. Raided Over '1 Billion Won Insider Trading Allegations'—The Key Question Is: Who Knew?
Attention is focusing on the scope of the case as executives and employees of ABL Bio Inc.(298380)(ABL Bio) are undergoing a compulsory investigation on suspicion of purchasing shares after gaining ad…
- 2026-09-15 15:46:02
- NA EUN-KYUNG
Technology
[Report] “Developing New Formulations with 40 Years of Expertise”… RPbio Inc. Sets Its Sights on Overseas Markets
“As a general rule, RPbio Inc.’s soft capsule production process requires that the prepared contents and coating be molded within 72 hours to maintain optimal quality. Typically, once the contents are…
- 2026-09-15 08:42:02
- KIM SUNG-JIN
Technology
KM Pharmaceutical Surges Despite Delisting; SK Biopharm Falls on FDA Hold [K-Bio Pulse]
Korean pharmaceutical and biotech stocks posted mixed results on September 11, with KM Pharmaceutical and BL Pharmtech both hitting their daily upper price limits. KM Pharmaceutical, in particular, su…
- 2026-09-15 08:28:03
- KIM SUNG-JIN
PHARM EDAILY
Shorts